TuHURA Biosciences, Inc./NV 8-K

What Happened

• TuHURA Biosciences, Inc. (HURA) filed an 8-K on July 7, 2026 disclosing that it drew an additional $1,900,000 under a previously announced Loan Agreement with Parkview Holdings One LLC.
• The Loan Agreement (entered April 21, 2026) provides a revolving credit facility with up to $50 million in availability and a maturity date of April 21, 2031. The June 30, 2026 draw is intended for general corporate purposes.

Key Details

• Lender: Parkview Holdings One LLC (the Loan Agreement was originally disclosed in an 8-K filed April 22, 2026 as Exhibit 4.1).
• Recent draw: $1,900,000 received and borrowed on June 30, 2026.
• Facility size and term: up to $50,000,000 in availability; maturity April 21, 2031.
• Risk/forward-looking notes in the filing highlight possible limits on draws, potential need for additional capital, and a disclosed risk of conflicts of interest because the lender is an affiliate of the company’s largest stockholder.

Why It Matters

• This draw increases TuHURA’s near-term liquidity by $1.9M and reflects use of the company’s revolving credit facility for general corporate needs.
• Investors should note the facility’s size and long-term maturity provide potential funding flexibility, but the company cautioned that availability is subject to conditions and may be insufficient to fund operations, and there may be governance considerations because of the lender’s affiliation with a major stockholder.
• Review the company’s March 31, 2026 Form 10-K and the April 22, 2026 8-K (Exhibit 4.1) for full Loan Agreement terms and related risks.